Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor


Por: Jimeno, J, Varona, JF, Lopez-Martin, JA, Izquierdo-Useros, N, Molina, EM, Guisado-Vasco, P, Sachse, M, Risco, C, Losada, A, Fudio, S, Luepke, E, Nieto, A, Gomez, J, Aviles, P, Cuevas, C, Bouhaddou, M, Sola, I, Krogan, NJ, Enjuanes, L, Fernandez-Sousa, JM, GarcIa-Sastre, A and White, K

Publicada: 1 dic 2025 Ahead of Print: 1 nov 2025
Resumen:
Selective pressures in the ocean promote the evolution of potent molecules that may be useful in therapeutic settings. Tunicates provide a rich source of bioactive molecules that have been shown to have anti-neoplastic and anti-microbial activities. Plitidepsin, a natural marine cyclic depsipeptide originally isolated from the tunicate Aplidium albicans, was originally developed as an anti-tumor drug, and has been approved for use in Australia in patients with advanced pretreated myeloma. Early in the SARS-CoV-2 pandemic, plitidepsin was shown to have potent preclinical efficacy against the virus, suggesting that it could be repurposed for the treatment of COVID-19. This review summarizes the clinical development of plitidepsin first as an anti-tumor drug, before providing a recapitulation of current efforts to repurpose the molecule as an antiviral therapy. The pharmacokinetic and pharmacodynamic data on plitidepsin will be analyzed, and the various experimental lines of evidence in support of the molecule's multifactorial mechanism of action will be explored. Finally, the available data on the use of plitidepsin in patients with COVID-19 will be presented, including results from a Phase I proof-of-concept study, real-world data from immunocompromised patients, and a look of results from a Phase III clinical trial that confirms the working hypothesis.

Filiaciones:
Jimeno, J:
 PharmaMar R&D, Madrid, Spain

 Novita Pharmaceut, New York, NY 10065 USA

Varona, JF:
 Univ Camilo Jose Cela, Hosp Univ HM Monteprincipe, HM Hosp, Dept Med Interna, Madrid, Spain

 Univ Camilo Jose Cela, Inst Invest Sanitaria HM Hosp, Fac HM Ciencias Salud CUHMED, Madrid, Spain

Lopez-Martin, JA:
 PharmaMar R&D, Madrid, Spain

 Atrys Hlth, Madrid, Spain

:
 IrsiCaixa, Barcelona, Spain

 Ctr Invest Biomed Red Enfermedades Infecciosas, CIBERINFEC, Madrid, Spain

 Inst Germans Trias & Pujol, Badalona, Spain

:
 IrsiCaixa, Barcelona, Spain

Guisado-Vasco, P:
 Hosp Univ Quironsalud, Dept Internal Med, Madrid, Spain

 European Univ, Madrid, Spain

Sachse, M:
 Univ Autonoma, Ctr Nacl Biotecnol Severo Ochoa, Madrid, Spain

Risco, C:
 Univ Autonoma, Ctr Nacl Biotecnol Severo Ochoa, Madrid, Spain

Losada, A:
 PharmaMar R&D, Madrid, Spain

Fudio, S:
 PharmaMar R&D, Madrid, Spain

Luepke, E:
 PharmaMar R&D, Madrid, Spain

Nieto, A:
 PharmaMar R&D, Madrid, Spain

Gomez, J:
 PharmaMar R&D, Madrid, Spain

Aviles, P:
 PharmaMar R&D, Madrid, Spain

Cuevas, C:
 PharmaMar R&D, Madrid, Spain

Bouhaddou, M:
 Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA

 J David Gladstone Inst, Quantitat Biosci Inst, San Francisco, CA USA

Krogan, NJ:
 J David Gladstone Inst, Quantitat Biosci Inst, San Francisco, CA USA

 Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA USA

 J David Gladstone Inst, Gladstone Inst Data Sci & Biotechnol, San Francisco, CA 94158 USA

 Quantitat Biosci Inst QBI, COVID 19 Res Grp QCRG, San Francisco, CA 94158 USA

Fernandez-Sousa, JM:
 PharmaMar R&D, Madrid, Spain

GarcIa-Sastre, A:
 Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA

 Icahn Sch Med Mt Sinai, Global Hlth Emerging Pathogens Inst, New York, NY USA

 Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY USA

 Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

 ISMMS, Dept Pathol Mol & Cell Based Med, New York, NY USA

 ISMMS, Icahn Genom Inst, New York, NY USA

White, K:
 Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA

 Icahn Sch Med Mt Sinai, Global Hlth Emerging Pathogens Inst, New York, NY USA
ISSN: 00982997





Molecular Aspects of Medicine
Editorial
Elsevier Ltd., RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, Reino Unido
Tipo de documento: Review
Volumen: 106 Número:
Páginas: 101412-101412
WOS Id: 001617965000001
ID de PubMed: 41218566

MÉTRICAS